Stock Monitor: Pluristem Therapeutics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / December 12, 2017 / Active-Investors issued a free report on VistaGen Therapeutics Inc. (NASDAQ: VTGN) ("VistaGen"), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=VTGN as the Company's latest news hit the wire. On December 08, 2017, the Company announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 9,834,754 regarding methods for producing hematopoietic precursor stem cells, which are stem cells that give rise to all of the blood cells and most of the bone marrow cells in the body, from human pluripotent stem cells (hPSCs). VistaGen holds an exclusive license to this patent from the University Health Network (UHN), Canada's largest research hospital. Sign up now for our free research reports at:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Pluristem Therapeutics Inc. (NASDAQ: PSTI), which also belongs to the Healthcare sector as the Company VistaGen Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=PSTI

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, VistaGen Therapeutics most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:

www.active-investors.com/registration-sg/?symbol=VTGN

Issued US Patent Technology Bears Potential to Impact Direct and Supportive Therapy for Autoimmune Disorders and Cancer

The technology covered by the issued US patent has the potential to impact both direct and supportive therapy for autoimmune disorders and cancer, with CAR-T cell applications, and foundational technology which may provide approaches for producing bone marrow stem cells for bone marrow transfusions. The breakthrough technology was discovered and developed by distinguished stem cell researcher, Dr. Gordon Keller, Director of the UHN's McEwen Centre for Regenerative Medicine in Toronto. Dr. Keller is the Co-Founder of VistaGen and a member of the Company's Scientific Advisory Board.

VistaGen Received Notice of Allowance from USPTO for US Patent in August

On August 08, 2017, the Company received a Notice of Allowance from the USPTO for US Patent Application No. 14/359,517 regarding proprietary methods for producing hematopoietic precursor stem cells.

VistaStem's Strategic Partnership with BlueRock Therapeutics

In December 2016, VistaGen's subsidiary, VistaStem Therapeutics, signed an exclusive sublicense agreement with BlueRock Therapeutics, a stem cell research Company established by Bayer AG and Versant Ventures, for VistaGen's rights to certain proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease. VistaGen licensed exclusive rights of the cardiac stem cell technologies from UHN. Pursuant to the agreement, VistaGen received an upfront cash payment of $1.25 million from BlueRock, as well as potential future milestone payments and royalties.

About Autoimmune Disorders

An autoimmune disease is a condition in which one's immune system mistakenly attacks the body, like joints or skin. It releases proteins called auto-antibodies that attack healthy cells. Some autoimmune diseases target only one organ. There are more than 80 types of autoimmune diseases, and some have similar symptoms. Often, the first symptoms are fatigue, muscle aches, and a low fever. The classic sign of an autoimmune disease is inflammation, which can cause redness, heat, pain, and swelling.

About VistaGen Therapeutics Inc.

Founded in 1998, VistaGen is a clinical-stage biopharmaceutical Company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders. The Company's lead CNS product candidate, AV-101, is a new generation oral antidepressant drug candidate in Phase-2 development. VistaGen is headquartered in San Francisco, California.

VistaStem Therapeutics is the wholly-owned subsidiary of VistaGen, focused on applying human pluripotent stem cell technology platform and CardioSafe 3D?, a customized in-vitro cardiac cell bioassay system, to predict potential heart toxicity of new chemical entities long before they are tested in pre-clinical animal studies and human clinical studies.

Stock Performance Snapshot

December 11, 2017 - At Monday's closing bell, VistaGen Therapeutics' stock tumbled 32.22%, ending the trading session at $1.22.

Volume traded for the day: 5.09 million shares, which was above the 3-month average volume of 1.14 million shares.

Stock performance in the last month ? up 48.78%

After yesterday's close, VistaGen Therapeutics' market cap was at $12.68 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors